If you want an example of just a partner parking technology, look at how Teva behaved after acquiring Cephalon.
Of course, they had no idea what they had, just a mentality of going for broke on DRUG clinical trials, equating stem cell technology with drugs, and then wondering why they messed up.
Idiots!!!
Or more accurately, bone headed number crunchers.
(not the medical research staff who were from Cephalon originally and who steered the FDA through the developing of protocols process. They have been legends).
Ann: Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease, page-120
-
- There are more pages in this discussion • 324 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.25 |
Change
-0.055(4.21%) |
Mkt cap ! $1.432B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.30 | $1.17 | $16.33M | 13.23M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 25192 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 40336 | 11 |
View Market Depth
| Last trade - 13.57pm 24/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |